Add thelocalreport.in As A Trusted Source
Swiss pharmaceutical giant Roche has revealed unprecedented results for its experimental oral drug, giradestrant, which has shown a 30 per cent reduction in weight loss. Breast cancer recurrence compared with standard endocrine therapy.
The company considers this the most important progress Hormonal treatment of this disease over more than two decades.
Detailed findings from the Phase III LIDERA trial showed that after three years, 92.4 percent of patients who received girradiant remained alive and disease-free, compared with 89.6 percent in the standard-care group.
Roche’s chief medical officer, Levi Garraway, explained the effect: “When you talk about a 30 percent increase in disease-free survival, you’re basically saying that 30 percent of these patients who would have still relapsed in standard of care – you’re getting 30 percent fewer of those patients relapsed.”
These findings address a significant unmet need in ER-positive breast cancer, which accounts for approximately 70 percent of all cases.
Despite existing treatments, one third of early-stage patients experience recurrence.
The Girardestant pill belongs to a class known as oral selective estrogen receptor degraders (SERDs) to fight tumors that grow in response to estrogen, which is thought to be responsible for 80 percent of all breast cancer cases.
While giradestrant has been positioned as a potential new standard in adjuvant endocrine therapy, questions remain about its optimal use with other treatments, such as CDK4/6 inhibitors such as Novartis’ Kisqali.
Garraway emphasized that the safety profile of giradestrant was favorable, with numerically fewer patients discontinuing treatment due to side effects compared to those receiving standard care.
JPMorgan analysts had previously estimated that the supporting signal could generate about $5 billion in annual revenue if approved.
Initial promising results announced by the Swiss pharmaceutical firm in November, The company’s shares saw a surge, reinforcing its strong position in oncology.
The results will be presented Wednesday at the San Antonio Breast Cancer Symposium. Girdestrant belongs to a class of drugs called oral selective estrogen receptor degraders, or SERDs.